jdh,
Thanks for slumming it and stopping by the ED forum from your usual place to impart your wisdom. The attendings really like it when you use the. Because honestly, we aren't. I'm only in it for the first million, then I'm going to be an investment banker.
Ahh. I see the "attendings" are unable to appreciate a little rhetoric. Too over your head?
I've noted this and it won't happen again.
Xaelia is going to break it big with medical informatics. I guess maybe that's why he is so into the stats/data. However, you and Fred are still practicing anecdote based medicine
And so are you, every . . . single . . . day. Hell, show me the randomized placebo controlled trial demonstrating the effectiveness of vasopressors in the first place. Why do we even use pressors in the first place, huh? Oh?! You mean because we all
anecdotally found that patients in many shock states lived when they had higher blood pressures? Whoa. Blows my freakin' mind.
and worse still, hiding behind the "physiology" argument.
Actually, no, I'm no hiding behind that argument. I first made the point that there is no excellent randomized trials here, and because of that appealed to physiology and first principles. Perhaps an "attending" can go back and re-rea what was said?
I guess this means you give renal dose dopamine, steroids, Xigris, and xopenex too
Renal dose dopamine was debunked with evidence years ago, steroids are still used in stress doses for patients that actually need them, activated protein C is now off the market and I couldn't use it if I wanted to, but no, it was not used even in patient's with APACHEII's >25 outside of the rare attending that wouldn't pull the plug without having said they did "everything". The data on xopenex is pretty clear.
Congratulations, an "attending" brought up a nice straw man or two, all of which actually illustrated my point and to what end? Hell, as long as we are coming up with wild accusations, you like smelling farts!! Amirite?!
While it may be difficult to make a double blind trial, it isn't impossible, as they've already compared dopamine and levophed in the ICU. They've compared PA catheters to non-invasive monitoring. They've compared Edwards catheters to lactate clearance.
It's not just difficult but may be damn near impossible the way we need it to be to get the kind of information we are looking for. The patient population is simply too heterogenous with respect to what brought them in, why they are in shock, and what else they have wrong with them chronically at baseline. If you had 10 years and multiple sites you probably could get enough septic shock patients from GNRs with the only chronic medical issues of DM2 and HTN to make a definitive case for, against, or equivalence of one pressor vs another but . . . then . . . only for THAT patient population infected with those bugs. The evidence can only say what it can say even with the best randomized trials. So we're left with trials like the recent norepi vs dopamine, which attempts to be so big that it can make a statement about "all comers", and when you look at "all comers" the difference in their primary end point, 28 day mortality, was no different, but when you look at the sub-group analysis for cardiogenic shock, these patients did worse. Wait. So what's going on here? Can we or can we not extrapolate this study like brainless, non-thinkink idiots or not? While the study was not designed, nor powered, to look at cardiogenic shock, there it is, this pesky sub-group analysis . . . yay . . . interrupting the simplicity that I was trying to add to my patient acre with EBM . . .
Many people much smarter than me (and maybe you, you never know) have looked into it and haven't been able to get much of a difference between epi and norepi, even though they hit different receptors.
No difference in
what? Compared where? I find them compared in one place "recently" and well with similar MAP goals, but more arrhythmias in the epi group. The bottom line for this was that epi can be generally used safely, and it was well received because most of the rest of the world either cannot afford or has no access to some of the newer and more expensive agents. Though, we are not having a discussion about which pressor is better in the jungles of africa - at least I wasn't, and maybe I should have clarified that better; I tend to assume on this message board at least we're talking about western hospital medicine as it's practiced in the united states - and if that is the context for the discussion, why would you start a pressor with higher rates of arrhythmias when you simply don't have to? Especially in light of the medicolegal liability environment we all work in.
The bottom line,
again, as I've pointed out more than once here is that you need to apply your brain, education, and training to the evidence available
and to that not available and come up with the best treatments possible for your patient. This should not come as a surprise to anyone posting on this board.